Author/Authors :
Dibra، نويسنده , , Alban and Ndrepepa، نويسنده , , Gjin and Mehilli، نويسنده , , Julinda and Pineck، نويسنده , , Susanne and Mayer، نويسنده , , Sandra and Bollwein، نويسنده , , Hildegard and Hausleiter، نويسنده , , Jِrg and Pache، نويسنده , , Jürgen and Schِmig، نويسنده , , Albert and Kastrati، نويسنده , , Adnan، نويسنده ,
Abstract :
The prognostic value of the newly defined impaired fasting glucose (IFG) range (100 to 109 mg/dl) for the outcomes of patients undergoing percutaneous coronary interventions is unknown. We assessed the composite of death or myocardial infarction at 1 year of follow-up in 189 patients with IFG and 801 patients with a normal fasting glucose (<100 mg/dl), all with stable angina. The 1-year cumulative rate of death or myocardial infarction was 10.3% in the IFG group and 4.4% in the normal fasting glucose group (p = 0.002). In the multivariate model, IFG was an independent predictor of the occurrence of death or myocardial infarction (adjusted hazard ratio 2.30, 95% confidence interval 1.29 to 4.08, p = 0.005). An IFG of 100 to 109 mg/dl in patients with stable angina who undergo percutaneous coronary intervention may identify a patient subset with an increased risk of death or myocardial infarction.
